AFRICA ( Commonwealth Union) _ The Guaifenesin TG syrup, produced by Punjab-based QP Pharmachem Ltd, was examined, and the WHO reported finding unacceptable amounts of diethylene glycol and ethylene glycol in the samples. Both substances are poisonous to people and may be lethal if swallowed on the other hand If anyone had become ill, it was not mentioned in the WHO statement.
The most recent warning comes months after the WHO linked child fatalities in The Gambia and Uzbekistan to other cough treatments made in India. Sudhir Pathak, managing director of QP Pharmachem, claims that after receiving the required regulatory permits, the company exported the batch of 18,346 bottles to Cambodia. He asserted that he was unaware of the route taken by the item to reach Micronesia and the Marshall Islands.
These bottles were not sent to the Pacific region, nor were they approved for use there. He continued, noting that his company has sent a legal notice to the company that sold the specific batch of drugs to Cambodia. According to the WHO statement, the medication, which is meant to treat symptoms of chest congestion and coughing, was evaluated by the Therapeutic Goods Administration, Australia’s medicines regulatory body. The syrup was advertised by Trillium Pharma, a business founded in the state of Haryana. The Indian government has not responded to the most recent concern. The statement said, Neither the stated manufacturer nor the marketer has provided guarantees to WHO on the safety and quality.
Why Indian-made Medications are raising safety worries
The majority of the medical needs of developing nations are provided by India, which is the largest exporter of generic medications in the world. But in recent months, a number of Indian companies have come under fire for the caliber of their pharmaceutical products, with experts voicing worries about the manufacturing procedures utilized to produce these drugs. In October, 66 children in The Gambia died from kidney disease caused by four cough syrups produced by Maiden Pharmaceuticals, causing WHO to issue a global alert. The Indian government and Maiden Pharmaceuticals both denied the accusations.
In March, India withdrew the company’s production license when it was discovered that its cough syrups were responsible for 18 child fatalities in Uzbekistan. The FDA revealed earlier this month that the Indian eye drop producer responsible for three fatalities and significant illnesses in the US had violated many safety standards.
